240 related articles for article (PubMed ID: 26334096)
1. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
[TBL] [Abstract][Full Text] [Related]
2. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Ferrero A; Logrippo V; Spanu PG; Fuso L; Perotto S; Daniele A; Zola P
Int J Gynecol Cancer; 2009 Dec; 19(9):1529-34. PubMed ID: 19955931
[TBL] [Abstract][Full Text] [Related]
4. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
[TBL] [Abstract][Full Text] [Related]
6. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.
Zeestraten EC; Speetjens FM; Welters MJ; Saadatmand S; Stynenbosch LF; Jongen R; Kapiteijn E; Gelderblom H; Nijman HW; Valentijn AR; Oostendorp J; Fathers LM; Drijfhout JW; van de Velde CJ; Kuppen PJ; van der Burg SH; Melief CJ
Int J Cancer; 2013 Apr; 132(7):1581-91. PubMed ID: 22948952
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Lund B; Hansen OP; Neijt JP; Theilade K; Hansen M
Anticancer Drugs; 1995 Dec; 6 Suppl 6():61-2. PubMed ID: 8718427
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Fuxius S; Mross K; Mansouri K; Unger C
Anticancer Drugs; 2002 Oct; 13(9):899-905. PubMed ID: 12394252
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
Peng P; Shen K; Yang JX; Wu M; Huang HF; Pan LY; Lang JH
Chin Med Sci J; 2007 Sep; 22(3):177-82. PubMed ID: 17966166
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Elshebeiny M; Almorsy W
J Egypt Natl Canc Inst; 2016 Sep; 28(3):183-9. PubMed ID: 27237370
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
17. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Petru E; Angleitner-Boubenizek L; Reinthaller A; Deibl M; Zeimet AG; Volgger B; Stempfl A; Marth C
Gynecol Oncol; 2006 Aug; 102(2):226-9. PubMed ID: 16443259
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
[TBL] [Abstract][Full Text] [Related]
19. [Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Chu P; Lu CH; Sheng XG; Zhou CX; Li DP; DU XL; Liu NF
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):808-12. PubMed ID: 21211276
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
Garcia AA; O'Meara A; Bahador A; Facio G; Jeffers S; Kim DY; Roman L
Gynecol Oncol; 2004 May; 93(2):493-8. PubMed ID: 15099968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
